Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.
about
Genetically engineered mouse models in oncology research and cancer medicineMutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory AgentsOncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy.IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting.Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune PathwaysImmunotherapeutic potential of oncolytic vaccinia virus.Anti-bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor-binding response, impairing tumor outgrowth.Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy.Chemotherapy, immunity and microbiota--a new triumvirate?Trick and treat: Ambushing recurrent tumors before they get out of the door.Poker face no more: cancer recurrence reveals its hand.Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.Strong in vivo antitumor responses induced by an antigen immobilized in nanogels via reducible bonds.Hsp90 Inhibition Reduces TLR5 Surface Expression and NF-κB Activation in Human Myeloid Leukemia THP-1 Cells.APOBEC3 Mediates Resistance to Oncolytic Viral Therapy
P2860
Q28079323-87CD2AB1-AF3A-43A8-9496-38485729B544Q35534823-C00534FD-326E-49DC-8ABF-900121D69F7BQ37129177-8B034FE1-C645-4F2C-9AF3-679C668E0929Q37676297-F6932F33-7CAD-4685-B784-EEEBE4CA07A1Q37690959-A73008EC-18F4-4131-A59A-62DC8D0E6044Q38225561-A2B1E7EB-62D0-4786-B11E-FBA6F1298070Q38778205-9BB77BBC-7833-41C1-AD61-3B3850197FFBQ38924557-FB251145-6F52-4CF1-B52D-2B9A8ED1E6D3Q41767351-8FDC5DE3-F6E6-4E71-9664-974DABEFB955Q42180796-01FC1E03-64E5-4DDE-8DD6-1DBE6469A208Q45175788-8FD6A13E-8671-42D0-8172-5887F8783048Q47781149-C8ED2CE0-20AC-4358-8C1F-8F76CD768702Q48974238-96DF54CF-D1B8-4654-B567-3E36952E27DAQ55401366-A9B5FE89-A344-4F0F-AE3E-7C862C5F41E5Q57192791-7760053B-689B-447C-BF5D-83F536E6D96D
P2860
Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Detecting and targeting tumor ...... effectors at early recurrence.
@en
Detecting and targeting tumor ...... effectors at early recurrence.
@en-gb
Detecting and targeting tumor ...... effectors at early recurrence.
@nl
type
label
Detecting and targeting tumor ...... effectors at early recurrence.
@en
Detecting and targeting tumor ...... effectors at early recurrence.
@en-gb
Detecting and targeting tumor ...... effectors at early recurrence.
@nl
prefLabel
Detecting and targeting tumor ...... effectors at early recurrence.
@en
Detecting and targeting tumor ...... effectors at early recurrence.
@en-gb
Detecting and targeting tumor ...... effectors at early recurrence.
@nl
P2093
P2860
P50
P356
P1433
P1476
Detecting and targeting tumor ...... effectors at early recurrence.
@en
P2093
Debabrata Mukhopadhyay
Diana Rommelfanger-Konkol
Hardev Pandha
Jill Thompson
Jose Pulido
Kevin Harrington
Matt Coffey
Richard Vile
Roger Kaspar
Rosa Maria Diaz
P2860
P2888
P304
P356
10.1038/NM.3397
P407
P5530
P577
2013-11-17T00:00:00Z
P6179
1001135341